May 18, 2018 09:45 AM EDTUpdated 10:07 AM
R&D

Ag­ile bris­tles af­ter FDA's third snub, promis­ing a fight for its con­tra­cep­tive

Brittany Meiling

Ag­ile Ther­a­peu­tics is start­ing to get testy af­ter suf­fer­ing yet an­oth­er snub from the FDA, an­nounc­ing this morn­ing that it sim­ply doesn’t agree with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times